Improperly issued drug patents can and do delay the entry of generic drugs. Indeed, a key strategy of brand-name pharmaceutical manufacturers is to obtain patents not just for active ingredients, but ...

A group of House lawmakers and the head of the Federal Trade Commission want Congress to include a provision in the health care legislation that they say could save American consumers several billion ...

Medicare plans are replacing brand-name buprenorphine-naloxone film with its generic equivalents, resulting in a decrease in out-of-pocket cost faced by enrollees with opioid use disorder. Objectives: ...

Remodulin and Adcirca have seen generic entry throughout 2018 and 2019, and we expect continued competition. Tyvaso and Orenitram will likely see generic entry in 2026 and 2027, respectively. While we ...